Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat ovarian cancer: drug duo enters phase 2 trial

NCT ID NCT05446298

Ongoing Disease control Sponsor: OncoC4, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two immunotherapy drugs, ONC-392 and pembrolizumab, can shrink tumors in people with platinum-resistant ovarian cancer. About 58 adults with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer are taking part. The goal is to see if the combination is safe and effective when standard treatments have stopped working.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm ovarian cancer ovarian carcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY OVARIAN CANCER PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

  • Baptist Health Lexington, 407

    Lexington, Kentucky, 40503, United States

  • Baptist MD Anderson Cancer Center, 404

    Jacksonville, Florida, 32207, United States

  • Cancer Treatment Centers of America, Chicago. 410

    Zion, Illinois, 60099, United States

  • Cancer Treatment Centers of America, Phoenix. 403

    Goodyear, Arizona, 85338, United States

  • Center of Hope, 413

    Reno, Nevada, 89511, United States

  • Honor Health, USOR, 406

    Phoenix, Arizona, 85082, United States

  • Medical College of Wisconsin, 408

    Milwaukee, Wisconsin, 53226, United States

  • Minnesota Oncology Hematology, P. A. - USOR, 421

    Maplewood, Minnesota, 55109, United States

  • Northwest Cancer Centers - Dyer, IN - USOR, 422

    Dyer, Indiana, 46311, United States

  • Norton Cancer Institute - St. Matthews, 416

    Louisville, Kentucky, 40207, United States

  • Nuvance Health System, 401

    Danbury, Connecticut, 06856, United States

  • Oncology Associates of Oregon, P. C. - USOR. 419

    Eugene, Oregon, 97401, United States

  • Sudarshan Sharma, MD. LTD. 414

    Hinsdale, Illinois, 60521, United States

  • Texas Oncology - Northeast Texas - USOR, 423

    Tyler, Texas, 75702, United States

  • Texas Oncology, P. A. - Austin, USOR. 417

    Austin, Texas, 78731, United States

  • Texas Oncology, P. A. Woodlands - USOR, 418

    The Woodlands, Texas, 77380, United States

  • Texas Oncology, P.A., Fort Worth - USOR. 420

    Fort Worth, Texas, 76104, United States

  • The Ohio State University James Cancer Center, 412

    Columbus, Ohio, 43210, United States

  • The Valley Hosptial, Inc. 411

    Ridgewood, New Jersey, 07450, United States

  • Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409

    Shreveport, Louisiana, 71103, United States

  • Women's Cancer Care Associates, LLC. 405

    Albany, New York, 12208, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.